Recent Publications 

 

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells.

Chowdhury SR, Peltier C, Hou S, Singh A, Johnston JB, Gibson SB, Marshall A, Banerji V. Cancers (Basel). 2021 Jan 19;13(2):354. doi: 10.3390/cancers13020354. PMID: 33477957; PMCID: PMC7835851.

​

Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment.

Roy Chowdhury S, Bouchard EDJ, Saleh R, Nugent Z, Peltier C, Mejia E, Hou S, McFall C, Squires M, Hewitt D, Davidson L, Shen GX, Johnston JB, Doucette C, Hatch GM, Fernyhough P, Marshall A, Gibson SB, Dawe DE, Banerji V.Cancers (Basel). 2020 Mar 11;12(3):650. doi: 10.3390/cancers12030650.

​

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC.Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.

​

Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia.

Banerji V, Anglin P, Christofides A, Doucette S, Laneuville P.Curr Oncol. 2020 Apr;27(2):e231-e245. doi: 10.3747/co.27.6291. Epub 2020 May 1.​

​

IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.

Assouline S, Amrein L, Aloyz R, Banerji V, Caplan S, Owen C, Hasegawa W, Robinson S, Shivakumar S, Prica A, Peters A, Hagerman L, Rodriguez L, Skamene T, Panasci L, Chen BE, Hay AE.Leuk Lymphoma. 2020 Mar 10:1-7. doi: 10.1080/10428194.2020.1734594. Online ahead of print.

​

An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring.

Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Lenis M, Kirubananthaan A, Mamedov A, Zhang L, Rockwood K, Buckstein R.Leukemia. 2020 May;34(5):1394-1406. doi: 10.1038/s41375-019-0666-7. Epub 2019 Dec 6.

​

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia.

Kost SEF, Saleh A, Mejia EM, Mostafizar M, Bouchard EDJ, Banerji V, Marshall AJ, Gibson SB, Johnston JB, Katyal S.Cancers (Basel). 2019 Oct 9;11(10):1519. doi: 10.3390/cancers11101519.

​

Complete resolution of chylopericardium after chemotherapy for chronic lymphocytic leukemia.

Morris AL, Colbourne T, Kirkpatrick I, Banerji V.Curr Oncol. 2019 Oct;26(5):e696-e699. doi: 10.3747/co.26.5039. Epub 2019 Oct 1.

​

Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.

Uminski K, Brown K, Bucher O, Hibbert I, Dhaliwal DH, Johnston JB, Geirnaert M, Dawe DE, Banerji V.Curr Oncol. 2019 Oct;26(5):e610-e617. doi: 10.3747/co.26.4957. Epub 2019 Oct 1.

​

Buccal cell telomere length is not a useful marker for comorbidities in chronic lymphocytic leukemia.

Yang L, Kost SEF, Beiggi S, Zhang Y, Schmidt R, Nugent Z, Marshall A, Banerji V, Gibson SB, Johnston JB.Leuk Res. 2019 Nov;86:106220. doi: 10.1016/j.leukres.2019.106220. Epub 2019 Aug 28.

​

IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.

Ishdorj G, Streu E, Lambert P, Dhaliwal HS, Mahmud SM, Gibson SB, Banerji V, Marshall AJ, Johnston JB.Blood Adv. 2019 Jul 23;3(14):2188-2198. doi: 10.1182/bloodadvances.2018026591.

​

Vasomotor symptoms and neurovegetative comorbidities on the menopause: insights from an Italian quantitative research.

Graziottin A, Banerji V, Hall G.Gynecol Endocrinol. 2019 Sep;35(9):762-766. doi: 10.1080/09513590.2019.1582625. Epub 2019 Jul 2.

​

Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival.

Ishdorj G, Beiggi S, Nugent Z, Streu E, Banerji V, Dhaliwal D, Mahmud SM, Marshall AJ, Gibson SB, Wiseman MC, Johnston JB.Leuk Lymphoma. 2019 Dec;60(13):3204-3213. doi: 10.1080/10428194.2019.1620941. Epub 2019 Jun 25.

​

Statin Use and Chronic Lymphocytic Leukemia Incidence: A Nested Case-Control Study in Manitoba, Canada.

Righolt CH, Zhang G, Ye X, Banerji V, Johnston JB, Gibson S, Mahmud SM.Cancer Epidemiol Biomarkers Prev. 2019 Sep;28(9):1495-1501. doi: 10.1158/1055-9965.EPI-19-0107. Epub 2019 Jun 11.

​

Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.

Ali AY, Guan Q, Wu X, Hou S, Banerji V, Johnston JB, Wall D, Szwajcer D, Gibson SB, Marshall AJ.Br J Haematol. 2019 Jun;185(5):883-887. doi: 10.1111/bjh.15865. Epub 2019 Mar 14.

​

​Click to View Older Publications

​